Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2350
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia ; volume:9 ; number:1 ; day:17 ; month:7 ; year:2008 ; pages:1-6 ; date:12.2008
BMC medical genetics ; 9, Heft 1 (17.7.2008), 1-6, 12.2008
- Urheber
-
Kim, Shin-Young
- Beteiligte Personen und Organisationen
-
Lim, Ji-Hyae
Yang, Jae-Hyug
Kim, Moon-Young
Han, Jung-Yeol
Ahn, Hyun-Kyong
Choi, Jun-Seek
Park, So-Yeon
Kim, Mi-jin
Ryu, Hyun-Mee
SpringerLink (Online service)
- DOI
-
10.1186/1471-2350-9-68
- URN
-
urn:nbn:de:1111-2016021834480
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
07.03.2025, 10:06 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Shin-Young
- Lim, Ji-Hyae
- Yang, Jae-Hyug
- Kim, Moon-Young
- Han, Jung-Yeol
- Ahn, Hyun-Kyong
- Choi, Jun-Seek
- Park, So-Yeon
- Kim, Mi-jin
- Ryu, Hyun-Mee
- SpringerLink (Online service)
Ähnliche Objekte (12)
Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
The angiogenic factors placental growth factor (PIGF) and soluble FMS-like tyrosine kinase 1 (sFlt-1) can be used for predicting preeclampsia and intrauterine growth restriction as well as classifying preeclampsia according to severity : = Die Angiogenesefaktoren Placental growth factor (PIGF) und soluble FMS-like tyrosine Kinase 1 (sFlt-1) könnten sowohl zur Prädiktion der Präeklampsie und der intrauterinen Wachstumsrestriktion, als auch für die Klassifikation des Schweregrades verwendet werden
Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
Die Wertigkeit von placental growth factor (PlGF) und soluble fms-like tyrosine kinase-1 (sFlt-1) im Rahmen des Erst-Trimester-Screenings.
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
FMS
FMS*
FMS
FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
The angiogenic factors placental growth factor (PIGF) and soluble FMS-like tyrosine kinase 1 (sFlt-1) can be used for predicting preeclampsia and intrauterine growth restriction as well as classifying preeclampsia according to severity : = Die Angiogenesefaktoren Placental growth factor (PIGF) und soluble FMS-like tyrosine Kinase 1 (sFlt-1) könnten sowohl zur Prädiktion der Präeklampsie und der intrauterinen Wachstumsrestriktion, als auch für die Klassifikation des Schweregrades verwendet werden
Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
Die Wertigkeit von placental growth factor (PlGF) und soluble fms-like tyrosine kinase-1 (sFlt-1) im Rahmen des Erst-Trimester-Screenings.
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
FMS
FMS*
FMS
FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia
Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsia, Pregnancy-induced Hypertension, and Proteinuria
The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trial
The angiogenic factors placental growth factor (PIGF) and soluble FMS-like tyrosine kinase 1 (sFlt-1) can be used for predicting preeclampsia and intrauterine growth restriction as well as classifying preeclampsia according to severity : = Die Angiogenesefaktoren Placental growth factor (PIGF) und soluble FMS-like tyrosine Kinase 1 (sFlt-1) könnten sowohl zur Prädiktion der Präeklampsie und der intrauterinen Wachstumsrestriktion, als auch für die Klassifikation des Schweregrades verwendet werden
Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
Die Wertigkeit von placental growth factor (PlGF) und soluble fms-like tyrosine kinase-1 (sFlt-1) im Rahmen des Erst-Trimester-Screenings.
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
FMS
FMS*
FMS